The listed-company investor lens — the honest debt story (net debt rose to ₹8,622 Cr / 4.35× through the capex cycle), the quality-of-earnings ladder, the EV → market-cap bridge at 0.22× sales, and the FY27 deleverage path that carries the re-rating case.
The market prices UFlex at ₹3,416 Cr — 0.22× sales, 0.42× book — because leverage ROSE through the capex cycle: 3.73× → 4.52× peak → 4.35× on net debt ₹8,622 Cr, ~1.15× of headroom to the modeled 5.5× ceiling. The re-rating case is the reverse walk: sweep to 3.95× by H2 FY27, prove the ₹276 Cr run-rate gap, and let 6.1× do the rest.
2 of 4 headline metrics improving vs prior · still off target: EBITDA (Reported) ₹1,984 Cr vs ₹2,400 Cr, Net Debt / EBITDA 4.3x vs 3.0x, Operating Cash Flow ₹992 Cr vs ₹1,200 Cr
Net debt built ₹1,779 Cr through FY26 funding ₹2,044 Cr of capex; the deleverage line is what the market is paid to doubt, and it is the biggest driver of the 0.22×-sales discount.
The lowest-% readiness item is the top execution risk: Leverage ROSE 3.73→4.35 through capex; FY27 sweep must show up in prints.
Hold FY27 capex ≤ ₹1,400 Cr, sweep OCF to debt as commissioned assets ramp — deleverage is the goal, not the achievement.
Net debt ₹8,622 Cr = 4.35× EBITDA, up from 3.73× (peak 4.52× in Q3); headroom to the 5.5× ceiling is ~1.15×.
Each day of DSO ties up ~₹42 Cr of working capital that could fund the FY27 debt paydown.
The cockpit is strong day-to-day — but this is the investor lens, and it starts with the uncomfortable line: leverage rose from 3.73× to 4.35× funding a visible ₹2,044 Cr capex cycle, and the market answers with a ₹3,416 Cr market cap on ₹15,401 Cr of revenue (0.22× sales, 0.42× book). Nothing here celebrates the level or hides the trend — it lays out the QoE ladder, the EV → market-cap bridge, the debt stack and the FY27 sweep that, if the prints confirm it, is the whole re-rating.
Reported ₹1,984 Cr → less FX/derivative gains → Normalized ₹1,910 Cr → annualize the Q4 exit (15.3%, 14-qtr high) → Egypt aseptic / recycling / WPP commissioning → films-cycle & tariff haircut → Run-rate (modeled).
So what: the gap between reported and run-rate is ₹276 Cr of EBITDA. Held at the same 6.1× the market pays today, that is worth ~₹1,684 Cr of enterprise value — roughly half the current market cap — which is exactly why the bridge must be audit-proof: the FX/derivative line is disclosed separately each quarter, and the Q4 15.3% is quoted as an exit rate, not a run-rate, with a −₹150 Cr cycle haircut against it.
Enterprise value → less net debt (gross ₹9,853 Cr − cash ₹1,231 Cr) → Equity value (market cap @ ₹473/sh) → less promoter holding 44.58% (pledge nil) → Public & institutional float.
The deep-value setup: net debt takes ₹8,622 Cr — 72% of the ₹12,038 Cr enterprise value — off the top, leaving a ₹3,416 Cr market cap on ₹15,401 Cr of revenue (0.22× sales, 0.42× book; contrast EPL at 2× the mcap on ⅓ the revenue). With promoters at 44.58% (pledge nil — 2.52% released during FY26), ₹1,893 Cr is the float the market prices. Deleverage + margin recovery + Asepto scale are the equity torque: every turn of leverage the FY27 sweep removes hands EV back to shareholders.
Debt BUILT every quarter of FY26 (capex ₹2,044 Cr — Egypt aseptic, Dharwad, Noida recycling, Mexico WPP); the sweep turns positive only in FY27 as commissioned assets ramp. Covenant ceiling 5.5× is modeled (CRISIL AA−/Stable); peak was 4.52× in Q3.
| Period | Beg net debt | Build / sweep | End net debt | LTM EBITDA | Leverage | Kind |
|---|---|---|---|---|---|---|
| Q1 FY26 (act) | ₹6,843 Cr | +₹463 Cr | ₹7,306 Cr | ₹1,874 Cr | 3.90× | Actual |
| Q2 FY26 (act) | ₹7,306 Cr | +₹447 Cr | ₹7,753 Cr | ₹1,794 Cr | 4.32× | Actual |
| Q3 FY26 (act) | ₹7,753 Cr | +₹428 Cr | ₹8,181 Cr | ₹1,810 Cr | 4.52× | Actual |
| Q4 FY26 (act) | ₹8,181 Cr | +₹441 Cr | ₹8,622 Cr | ₹1,984 Cr | 4.35× | Actual |
| H1 FY27 (fcst) | ₹8,622 Cr | −₹222 Cr | ₹8,400 Cr | ₹2,025 Cr | 4.15× | Forecast |
| H2 FY27 (fcst) | ₹8,400 Cr | −₹300 Cr | ₹8,100 Cr | ₹2,050 Cr | 3.95× | Forecast |
MCLR-linked India term loans for the capex program; USD/EUR debt at the overseas Flex Films entities (natural-hedged by exports); working-capital lines funding the 92-day DSO / 97-day inventory cycle. Tranche split modeled to foot to the real gross.
| Tranche | Kind | Balance | Rate | Maturity | Note |
|---|---|---|---|---|---|
| Term loans — India (aseptic, films, recycling capex) | Term | ₹3,900 Cr | ~8.9% (MCLR-linked) | 2027-2033 | Sanand, Panipat, Noida recycling & Dharwad programs. |
| Overseas subsidiary debt — Flex Films entities (USD/EUR) | Term | ₹2,950 Cr | SOFR + 250-320 bps | 2027-2031 | Egypt / Mexico / Europe plant financing; natural-hedged by export earnings. |
| Working-capital facilities (resin & receivables) | Revolver | ₹2,400 Cr | ~8.5% | Annual renewal | Funds the 92-day DSO / 97-day inventory cycle; LC-backed resin imports. |
| NCDs, leases & other borrowings | Term | ₹603 Cr | ~9.2% | 2027-2029 | Incl. ~₹300 Cr lease liabilities reported outside gross debt by screeners. |
Retention dips at scale-up, then recovers as CPG programs qualify and mature.
| Business | Since | NRR at launch | Yr 1 (dip) | NRR now | Yr-1 attrition | Note |
|---|---|---|---|---|---|---|
| Flexible Packaging (Laminates & Pouches) | 1988 | 99% | 100% | 106% | 5% | CPG laminate contracts compound with SKUs & formats. |
| Flex Films (Global Films) | 1994 | 100% | 98% | 102% | 8% | Commodity films reprice each cycle; retention is share, not price. |
| UFlex Holography & Security | 1999 | 98% | 97% | 108% | 6% | Security & brand-protection programs renew with compliance cycles. |
| Asepto (Aseptic Liquid Packaging) | 2017 | 96% | 99% | 111% | 4% | Dairy/juice/liquor cartons stick once lines are qualified — 7.78 → 7.97 bn packs. |
| F-TPM / F-WSP (Specialty Films) | 2019 | 97% | 96% | 109% | 6% | F-TPM / F-WSP / Alox premium programs expand within global CPGs. |
| Asclepius (90% PCR Film) | 2023 | 95% | 98% | 109% | 7% | EPR mandates pull PCR programs; young cohort, steep ramp. |
Scale-up dips the base early, then maturing programs recover it above 105 — except Flex Films (Global Films), where commodity-film repricing caps retention at 102 — the one soft spot investors will probe in the revenue-quality pack, and the reason the value-added mix shift is the strategy.
The top execution risk is the lowest-% item — 4.35× → 3.0× glide path with covenant headroom ≥1× (62%): Leverage ROSE 3.73→4.35 through capex; FY27 sweep must show up in prints.